Literature DB >> 19178920

Evaluation of three years of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma.

Jeremiah Ngondi1, Teshome Gebre, Estifanos B Shargie, Liknaw Adamu, Yeshewamebrat Ejigsemahu, Tesfaye Teferi, Mulat Zerihun, Berhan Ayele, Vicky Cevallos, Jonathan King, Paul M Emerson.   

Abstract

Trachoma surveys were conducted at baseline in five districts of Amhara National Regional State, Ethiopia (7478 participants in 1096 households) and at 3-year evaluation (5762 participants in 1117 households). Uptake of SAFE was assessed with programme monitoring data and interviews, and children (1-6 years) were swabbed for detection of ocular Chlamydia. At evaluation, 23,933 people had received trichiasis surgery; 93% of participants reported taking azithromycin at least once; 67% of household respondents (range 46-93) reported participation in trachoma health education; and household latrine coverage increased from 2% to 34%. In children aged 1-9 years percentage decline, by district, for outcomes was: 32% (95% CI 19-48) to 88% (95% CI 83-91) for trachomatous inflammation-follicular (TF); 87% (95% CI 83-91) to 99% (95% CI 97-100) for trachomatous inflammation-intense (TI); and 31% increase (95% CI -42 to -19) to 89% decrease (95% CI 85-93) for unclean face; and in adults percentage decline in trichiasis was 45% (95% CI -13 to 78) to 92% (95% CI 78-96). Overall prevalence of swabs positive for ocular Chlamydia was 3.1%. Although there were substantial reductions in outcomes in children and adults, the presence of ocular Chlamydia and TF in children suggests ongoing transmission. Continued implementation of SAFE is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19178920     DOI: 10.1016/j.trstmh.2008.11.023

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  30 in total

1.  The association between latrine use and trachoma: a secondary cohort analysis from a randomized clinical trial.

Authors:  Meron Haile; Zerihun Tadesse; Sintayehu Gebreselassie; Berhan Ayele; Teshome Gebre; Sun N Yu; Nicole E Stoller; Bruce D Gaynor; Travis C Porco; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

2.  Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020?

Authors:  Emma M Harding-Esch; Tansy Edwards; Ansumana Sillah; Isatou Sarr; Chrissy H Roberts; Paul Snell; Esther Aryee; Sandra Molina; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2009-12-22

3.  Risk of trachoma in a SAFE intervention area.

Authors:  Assegid Aga Roba; Daksha Patel; Marcia Zondervan
Journal:  Int Ophthalmol       Date:  2012-10-10       Impact factor: 2.031

4.  Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial.

Authors:  Nicole E Stoller; Teshome Gebre; Berhan Ayele; Mulat Zerihun; Yared Assefa; Dereje Habte; Zhaoxia Zhou; Travis C Porco; Jeremy D Keenan; Jenafir I House; Bruce D Gaynor; Thomas M Lietman; Paul M Emerson
Journal:  Int Health       Date:  2011-06       Impact factor: 2.473

5.  Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.

Authors:  Jeremy D Keenan; Berhan Ayele; Teshome Gebre; Jeanne Moncada; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Charles E McCulloch; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2011-11-17       Impact factor: 9.079

6.  The population-based prevalence of trachomatous scarring in a trachoma hyperendemic setting: results from 152 impact surveys in Amhara, Ethiopia.

Authors:  Tigist Astale; Caleb D Ebert; Andrew W Nute; Mulat Zerihun; Demelash Gessese; Berhanu Melak; Eshetu Sata; Zebene Ayele; Gedefaw Ayenew; E Kelly Callahan; Mahteme Haile; Taye Zeru; Zerihun Tadesse; Scott D Nash
Journal:  BMC Ophthalmol       Date:  2021-05-13       Impact factor: 2.209

7.  Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx.

Authors:  Rebecca A Gladstone; Ebrima Bojang; John Hart; Emma M Harding-Esch; David Mabey; Ansumana Sillah; Robin L Bailey; Sarah E Burr; Anna Roca; Stephen D Bentley; Martin J Holland
Journal:  Clin Microbiol Infect       Date:  2020-08-01       Impact factor: 8.067

Review 8.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

9.  Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.

Authors:  Emma M Harding-Esch; Ansumana Sillah; Tansy Edwards; Sarah E Burr; John D Hart; Hassan Joof; Mass Laye; Pateh Makalo; Ahmed Manjang; Sandra Molina; Isatou Sarr-Sissoho; Thomas C Quinn; Tom Lietman; Martin J Holland; David Mabey; Sheila K West; Robin Bailey
Journal:  PLoS Negl Trop Dis       Date:  2013-06-13

10.  Intestinal parasite prevalence in an area of ethiopia after implementing the SAFE strategy, enhanced outreach services, and health extension program.

Authors:  Jonathan D King; Tekola Endeshaw; Elisabeth Escher; Genetu Alemtaye; Sileabatt Melaku; Woyneshet Gelaye; Abebe Worku; Mitku Adugna; Berhanu Melak; Tesfaye Teferi; Mulat Zerihun; Demelash Gesese; Zerihun Tadesse; Aryc W Mosher; Peter Odermatt; Jürg Utzinger; Hanspeter Marti; Jeremiah Ngondi; Donald R Hopkins; Paul M Emerson
Journal:  PLoS Negl Trop Dis       Date:  2013-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.